This was disappointing in view of promising in vitro studies with dasatinib demonstrating growth inhibition of cells isolated from AML and JMML patients with c-Cbl RING finger and linker domain mutations [18], [19]. Here, CBL is linked to juvenile myelomonocytic leukemia.